Search

Your search keyword '"Histone Deacetylases metabolism"' showing total 682 results

Search Constraints

Start Over You searched for: Descriptor "Histone Deacetylases metabolism" Remove constraint Descriptor: "Histone Deacetylases metabolism" Topic antineoplastic agents Remove constraint Topic: antineoplastic agents
682 results on '"Histone Deacetylases metabolism"'

Search Results

1. Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells.

2. Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids.

3. Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia.

4. Utilization of an optimized AlphaFold protein model for structure-based design of a selective HDAC11 inhibitor with anti-neuroblastoma activity.

5. Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity.

6. Heterocycles-Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years.

7. Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death.

8. Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer.

9. Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects.

10. Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia.

11. Histone deacetylases: potential therapeutic targets in cisplatin-induced acute kidney injury.

12. Design and synthesis of triazolopyridine derivatives as potent JAK/HDAC dual inhibitors with broad-spectrum antiproliferative activity.

13. Synthesis and biological evaluation of ortho -phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases.

14. Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy.

15. Enhancing anti-cancer capacity: Novel class I/II HDAC inhibitors modulate EMT, cell cycle, and apoptosis pathways.

16. Synthesis and cytotoxic evaluation of heterocyclic compounds by vinylic substitution of ketene dithioacetals.

17. Discovering novel derivatives of STAT3 and HDAC inhibitors with anti-tumor activity.

18. Evaluation of 1,10-phenanthroline-based hydroxamate derivative as dual histone deacetylases/ribonucleotide reductase inhibitor with antitumor activities.

19. In-silico design of novel potential HDAC inhibitors from indazole derivatives targeting breast cancer through QSAR, molecular docking and pharmacokinetics studies.

20. Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax.

21. Discovery of novel benzimidazole derivatives as potent HDACs inhibitors against leukemia with (Thio)Hydantoin as zinc-binding moiety: Design, synthesis, enzyme inhibition, and cellular mechanistic study.

22. Design, synthesis and mechanistic study of new dual targeting HDAC/tubulin inhibitors.

23. Design, Synthesis, and Structure-Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition.

24. Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition.

25. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.

26. Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents.

27. The Importance of Structural Water in HDAC8 for Correct Binding Pose Applied for Drug Design of Anticancer Molecules.

28. Evaluation and molecular docking study of two flavonoids from Oroxylum indicum (L.) Kurz and their semi-synthetic derivatives as histone deacetylase inhibitors.

29. Discovery and Development of HDAC Inhibitors: Approaches for the Treatment of Cancer a Mini-review.

30. Coumarin-derived Hydroxamic Acids as Histone Deacetylase Inhibitors: A Review of Anti-cancer Activities.

31. Key structural requirements of benzamide derivatives for histone deacetylase inhibition: design, synthesis and biological evaluation.

32. Design, synthesis, and histone deacetylase inhibition study of novel 4-(2-aminoethyl) phenol derivatives.

33. The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy.

34. Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning.

35. Targeted small molecule therapy and inhibitors for lymphoma.

36. Combined In Silico and In Vitro Analyses to Assess the Anticancer Potential of Thiazolidinedione-Thiosemicarbazone Hybrid Molecules.

37. Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities.

38. Antineoplastic activity of plant-derived compounds mediated through inhibition of histone deacetylase: a review.

39. Discovery of novel polysubstituted N -alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy.

40. Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from β -elemene scaffold.

41. Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting.

42. Harnessing pyrimidine as a building block for histone deacetylase inhibitors.

43. Design, Synthesis, and Biological Evaluation of New Urushiol Derivatives as Potent Class I Histone Deacetylase Inhibitors.

44. Discovery of chiral 1,4-diarylazetidin-2-one-based hydroxamic acid derivatives as novel tubulin polymerization inhibitors with histone deacetylase inhibitory activity.

45. Melatonin-vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat.

46. Anticancer clinical efficiency and stochastic mechanisms of belinostat.

47. Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design.

48. Electrochemical Synthesis of New Isoxazoles and Triazoles Tethered with Thiouracil Base as Inhibitors of Histone Deacetylases in Human Breast Cancer Cells.

49. Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor.

50. Design and synthesis of novel uracil-linked Schiff bases as dual histone deacetylase type II/topoisomerase type I inhibitors with apoptotic potential.

Catalog

Books, media, physical & digital resources